Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Sabouret

Showing results (1-10 of 131) with videos related to

Pageof 14
Sort By:
European Journal of Preventive Cardiology|February 8, 2024
Coronary artery calcium score in the young: is it time to update the guidelines?Pierre Sabouret, Raul D Santos
Minerva Cardiology and Angiology|January 11, 2021
Racial differences in Takotsubo cardiomyopathy: more alike than different?Erin D Michos, Pierre Sabouret
Advances in Medical Sciences|February 28, 2026
Association between lipoprotein (a) and lipid profile and body composition in patients with high cardiovascular riskJoanna Popiolek-Kalisz, Pierre Sabouret
Archives of Cardiovascular Diseases|March 18, 2014
New antiplatelet agents in the treatment of acute coronary syndromesPierre Sabouret, Magali Taiel-Sartral
The New England Journal of Medicine|July 24, 2024
Semaglutide, Obesity-Related Heart Failure, and Type 2 DiabetesCharlotte Cohen, Régis Cohen, Pierre Sabouret
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|April 28, 2018
FOURIER to ODYSSEY: the end of the journey for lipid-lowering therapy trials? Lessons from recent clinical trials with anti-PCSK9 antibodiesPierre Sabouret, Denis Angoulvant, Atul Pathak
Atherosclerosis|January 14, 2025
New options for young people with dyslipidemia: The future is bright!Pierre Sabouret, Marco Bernardi, Elad Asher
Presse Medicale (Paris, France : 1983)|March 12, 2019
[PCSK9 inhibitors: What place in the management of dyslipidemia?]Pierre Sabouret, Michel Farnier, Etienne Puymirat
Journal of Cardiovascular Medicine (Hagerstown, Md.)|May 26, 2026
Clopidogrel vs. aspirin after percutaneous coronary intervention: consistent evidence across high-risk subgroupsAhmed Ibrahim, Pierre Sabouret, Giuseppe Andò
European Journal of Preventive Cardiology|February 10, 2024
Homocysteine: a futile comeback or a promising tool for the risk assessment of hypertensive patients?Marco Bernardi, Francesco Paneni, Pierre Sabouret
Pageof 14

Showing results (1-10 of 131) with videos related to

Sort By:
Pageof 14
European Journal of Preventive Cardiology|February 8, 2024
Coronary artery calcium score in the young: is it time to update the guidelines?Pierre Sabouret, Raul D Santos
Minerva Cardiology and Angiology|January 11, 2021
Racial differences in Takotsubo cardiomyopathy: more alike than different?Erin D Michos, Pierre Sabouret
Advances in Medical Sciences|February 28, 2026
Association between lipoprotein (a) and lipid profile and body composition in patients with high cardiovascular riskJoanna Popiolek-Kalisz, Pierre Sabouret
Archives of Cardiovascular Diseases|March 18, 2014
New antiplatelet agents in the treatment of acute coronary syndromesPierre Sabouret, Magali Taiel-Sartral
The New England Journal of Medicine|July 24, 2024
Semaglutide, Obesity-Related Heart Failure, and Type 2 DiabetesCharlotte Cohen, Régis Cohen, Pierre Sabouret
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|April 28, 2018
FOURIER to ODYSSEY: the end of the journey for lipid-lowering therapy trials? Lessons from recent clinical trials with anti-PCSK9 antibodiesPierre Sabouret, Denis Angoulvant, Atul Pathak
Atherosclerosis|January 14, 2025
New options for young people with dyslipidemia: The future is bright!Pierre Sabouret, Marco Bernardi, Elad Asher
Presse Medicale (Paris, France : 1983)|March 12, 2019
[PCSK9 inhibitors: What place in the management of dyslipidemia?]Pierre Sabouret, Michel Farnier, Etienne Puymirat
Journal of Cardiovascular Medicine (Hagerstown, Md.)|May 26, 2026
Clopidogrel vs. aspirin after percutaneous coronary intervention: consistent evidence across high-risk subgroupsAhmed Ibrahim, Pierre Sabouret, Giuseppe Andò
European Journal of Preventive Cardiology|February 10, 2024
Homocysteine: a futile comeback or a promising tool for the risk assessment of hypertensive patients?Marco Bernardi, Francesco Paneni, Pierre Sabouret
Pageof 14